STEVENSON, Md., Oct. 17, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of MGT Capital Investments, Inc. (NYSE MKT:MGT) (“MGT” or the “Company”) securities during the period between May 9, 2016 and September 20, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until November 21, 2016 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in MGT securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period the risk that its stock to be issued in connection with the acquisitions of D-Vasive, Inc. and Demonsaw LLC may not be listed by the New York Stock Exchange (“NYSE”) and that MGT was under inquiry by the U.S. Securities and Exchange Commission (“SEC”) prior to September 19, 2016.
According to the complaint, following a September 19, 2016 announcement that the Company had received a subpoena from the SEC days earlier, and a September 20, 2016 announcement that the NYSE was refusing to list the newly-issued stock of MGT required to complete the acquisitions, the value of MGT shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in MGT securities purchased on or after May 9, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 



